AI assistant
Sending…
aTYR PHARMA INC — Director's Dealing 2024
Jun 3, 2024
34337_dirs_2024-06-03_4f4ee098-05b0-467e-9e3c-55724563ac07.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2024-05-31
Reporting Person: Shukla Sanjay (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-31 | Common Stock | P | 20000 | $1.8070 | Acquired | 136548 | Direct |
Footnotes
F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.77 to $1.86 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
More from aTYR PHARMA INC
Report Publication Announcement
2026
Jun 1
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 11
Regulatory Filings
2026
Mar 26
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Jan 9